Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01783977 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 143
- Enrollment target
NCT01783977: Completed Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT01783977 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 143 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (138% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01783977, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 143 participants
- Enrollment target
Study Summary
NOTE: This study has stopped enrolling new participants, and all study vaccinations for currently enrolled participants have been stopped. Currently, there are no vaccines approved for the prevention of HIV infection, but there are many clinical trials taking place that are studying experimental HIV vaccines. The purpose of this study is to evaluate the safety and tolerability of three different HIV vaccine schedules in healthy, HIV-uninfected adults.
Interventions
- BIOLOGICAL DNA-HIV-PT123 vaccine
- BIOLOGICAL NYVAC-HIV-PT1 vaccine
- BIOLOGICAL NYVAC-HIV-PT4 vaccine
- BIOLOGICAL Placebo for DNA-HIV-PT123 vaccine
- BIOLOGICAL Placebo for NYVAC-HIV-PT1 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2013-04 |
| Est. Completion | 2018-10-24 |
| Phase | Phase 1 |
What the finished NCT01783977 record still lists
NCT01783977 is an interventional study that assigns participants to a tested intervention. The registered 143 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (138% higher).
The record links to 0 conditions, and to 5 interventions - of which DNA-HIV-PT123 vaccine is the first listed.
NCT01783977 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01783977 about?
NCT01783977 is a clinical study titled "Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults". NOTE: This study has stopped enrolling new participants, and all study vaccinations for currently enrolled participants have been stopped. Currently, there are no vaccines approved for the prevention of HIV infection, but there are many clinical trials taking place that are studying experimental HI...
What is the current status of trial NCT01783977?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 143 participants. The study started on 2013-04. Estimated completion is 2018-10-24.
What interventions are being tested in trial NCT01783977?
The interventions under investigation include: DNA-HIV-PT123 vaccine (BIOLOGICAL), NYVAC-HIV-PT1 vaccine (BIOLOGICAL), NYVAC-HIV-PT4 vaccine (BIOLOGICAL), Placebo for DNA-HIV-PT123 vaccine (BIOLOGICAL), Placebo for NYVAC-HIV-PT1 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01783977?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01783977's enrollment target sits among peer trials
143 401st of 2000 higher than 1,600 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia